Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
-
Recent studies showed that the neutrophil-to-lymphocyte ratio (NLR) and that platelet-to-lymphocyte ratio (PLR) can be used as inflammatory markers in Bell's palsy. In this study, the aim is to investigate a novel inflammatory index, the Systemic Immune-Inflammation Index (SII), defined as SII = platelets × neutrophils/lymphocytes, in Bell's palsy patients. ⋯ Bell's palsy has an inflammatory component. The SII value can indicate an inflammatory condition in these patients. It may be used as a marker and prognostic indicator in Bell's palsy.
-
To determine whether erenumab is effective and safe in refractory chronic migraine with medication overuse headache. ⋯ Erenumab reduced significantly migraine frequency and pain medication intake in refractory chronic migraine with MOH patients.
-
The objective of this study is to estimate the reference values of the brachial plexus roots at the interscalene groove. The physical and demographic characteristics of 59 healthy adult volunteers were studied. The CSA reference values and their correlations with weight, height, age, body mass index (BMI). ⋯ The CSA reference values of the C5-C7 nerve roots has been determined in asymptomatic individuals and can serve as a reference when studying pathological conditions of these structures.
-
To compare the amplitude changes in motor evoked potentials (MEP) with reversal of residual neuromuscular blockade using sugammadex or placebo in patients with cervical myelopathy. ⋯ Our study showed that there was a 200% increase in the MEP amplitude in the first dorsal interosseous muscle at 3 min following reversal of residual neuromuscular blockade with sugammadex. By ensuring that maximal MEP amplitude is recorded at baseline, early commencement of neuromonitoring can be achieved.
-
Multicenter Study
Adult brainstem glioma: a multicentre retrospective analysis of 47 Italian patients.
Adult brainstem gliomas are rare primary brain tumours with heterogeneous clinical course. The low frequency of these tumours makes it difficult to achieve high-quality evidence regarding prognostic factors, adequate therapeutic approach and outcome in such patients. ⋯ Further prospective multicentre efforts, and hopefully clinical trials, are necessary to improve outcome in this neglected glioma patient population.